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INTRODUCTION
Primary infection with polyoma BK virus (BKV) mostly
occurs during childhood. Usually it is asymptomatic and
adult seroprevalence is 60–90% in the general population
(Knowles et al., 2003; Egli et al., 2009). After primary in-
fection, the virus persists in a latent state in target cells,
mainly epithelial cells in the kidney and urinary tract (Ches-
ters et al., 1983). Virus reactivation can occur as viruria
and/or viremia. In healthy adults virus reactivation is inter-
mittent and in rare cases can be detected as low grade
viruria (Polo et al., 2004). In most cases an active BKV in-
fection develops within a year after kidney transplantation
(Hirsch et al., 2002; Vasudev et al., 2005). In 30–50% kid-
ney transplant recipients viruria progresses to viremia
(Bonvoisin et al., 2008). An active BKV virus infection can
cause lesion in the graft known as polyoma BK virus
nephropathy (BKVN) (Hirsch et al., 2002). BKVN causes
progression of graft dysfunction and can lead to premature
graft loss (Ramos et al., 2002). It affects 1–10% of renal
transplant recipients, and has become more widespread
since 1995 due to more potent immunosuppression avail-
ability (Binet et al., 1999). Therefore, the mainstay of ther-
apy for polyoma BKV nephropathy is to reduce or discon-
tinue immunosuppressive drugs (Comoli et al., 2006). As
no anti-BKV drugs exist and no evidence-based recommen-
dations can be made for the treatment of active BKV infec-
tion (Hirsch et al., 2009), each transplantation centre has its
own strategy. The aim of this paper is to summarize our ex-
perience in the treatment of active BKV infection.
MATERIALS AND METHODS
Study cohort. The study was performed in the Latvian
Transplantation Centre of Pauls Stradiòð Clinical University
Hospital in cooperation with the Institute of Pathology and
Department of Oncovirology of the Augusts Kirhenðteins
Institute of Microbiology and Virology in Rîga Stradiòð
University. The prospective study included 50 renal trans-
plant recipients (mean age 46 ± 13.8 years, 52% males) who
underwent deceased donor transplantation in 2007. That
kidney transplantation was the first for 41 (82%) patients
and the second for 9 (18%) patients. All patients with two
consecutive positive BK viremia measurements or patients
who developed an unexplained elevation of serum creati-
nine underwent a kidney graft biopsy to evaluate BKVN.
Acute rejection was defined by Banff criteria (Sis et al.,
2010). The study was approved by the Ethics Committee of
Rîga Stradiòð University.
Immunosuppression. All patients included in this study re-
ceived induction immunosuppression during kidney allo-
grafting surgery, and included an agent that contained anti-
CD25 monoclonal antibody, i.e., basiliximab 20 mg intrave-
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BK virus (BKV) infection was studied prospectively in 50 unselected consecutive patients who
had undergone kidney transplantation. Infection was monitored for one year after transplantation.
Viral DNA in urine (viruria) and plasma (viremia) samples was detected by nested, qualitative po-
lymerase chain reaction. BKV screening data was available for 92% (n = 46) of patients enrolled
in the study. Four groups of patients were distinguished: uninfected patients (group 1, n = 30), pa-
tients with viruria (group 2, n = 3), patients with viremia (group 3, n = 6) and patients with devel-
oped BKV nephropathy (group 4, n = 7). Infection was observed starting form the first month, and
the maximum number of patients with active BKV infection occurred at six months after transplan-
tation. Five-year graft survival was 69% for patients with any evidence of BKV infection, com-
pared with 80.0% (P = NS) for patients without BKV infection. The best graft function was
observed in group one patient (mean serum creatinine 130 mkmol/l and glomerular filtration rate
(GFR) 60.9 ml/min) and the worst in group 4 (mean serum creatinine 180 mkmol/l and GFR 52.31
ml/min) at five years after transplantation. Five-year patient survival was 82.6% and was not af-
fected by presence of BKV infection.
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nously on days 0 and 4, daclizumab 1 mg/kg intravenously
on days 0 and 15, or the polyclonal antibody antilympho-
cyte globulin (ATG) 1.5–3 mg/kg intravenously on the first
3–5 post-transplant days. The initial maintenance immuno-
suppression in all patients consisted of methylprednisolone
given intravenously in doses of 500 mg on the day of the
surgery, gradually over five days, followed by doses of oral
prednisone starting from 0.5 mg/kg per day and gradually
reduced such that the average dose after a month was 20 mg
per day and that after six months was 5–10 mg per day. Cal-
cineurin inhibitors and antiproliferative drugs were given on
the first postoperative day. Two antifroliferative drugs were
used: mycophenolate mofetil (MMF) at initial average dose
2 g per day orally, or azathioprine (AZA) at initial dose
100–150 mg per day orally adjusted per white blood cells
count. Two calcineurin inhibitors were used: cyclosporine
A (CSA) at initial average dose 3–4 mg/kg per day orally
adjusted to a trough level in blood of 150–200 ng/ml during
the first 3 post-transplant months and 100–200 ng/ml subse-
quently. The other calcineurin inhibitor, which was received
by some patients after treatment of severe acute rejection,
was tacrolimus (TAC). Tacrolimus was initiated at 0.1
mg/kg per day oral, aiming whole blood trough level of
5–10 ng/ml during the first three months and 4–8 ng/ml
subsequently. Patients who developed side effects of calci-
neurin inhibitors received sirolimus at initial dose 2 mg per
day orally, targeting a trough blood level of 5–10 ng/ml. All
patients experiencing an acute rejection episode as proved
by biopsy were treated with 3–5 boluses of intravenous
methylprednisolone. Steroid-resistant rejections were
treated with ATG (1.5–3 mg/kg per day intravenously over
10–14 days).
Diagnostics of BKV infection. During the study, virus in-
fections diagnostics was performed before kidney transplan-
tation, two weeks after surgery and further every three
months during the first post-transplant year, i.e., on the 3rd,
6th, 9th and 12th post-transplant month. Blood from the pe-
ripheral vein was collected in a blood tube with anticoagu-
lant (EDTA), and a middle portion of the morning urine
flow was collected in a sterile urine container. Qualitative
nested polymerase chain reaction (PCR) testing was per-
formed to detect BKV infection. Markers of the active viral
infection were viral sequences in the DNA isolated from the
cell-free plasma (viremia) or urine (viruria).
Management of BKV infection. Patients diagnosed for
BKV in two consecutive measurements and/ or developing
viral cytopathic changes characteristic for BKVN were as-
sumed to have their immunosuppression reduced., The cur-
rently available guidelines about immunosuppression reduc-
tion schemes had not ben published yet in the time period of
the study (2007 to 2008). For that reason, immunosup-
pression was reduced with caution. The MMF dose was re-
duced by 500 mg per day or MMF was switched to
azathioprine, or the cyclosporine dose was reduced by 50
mg per day, or the tacrolimus dose was reduced by 1–2 mg
per day.
Statistics. Data are presented as means ± SD or counts and
percentages, as appropriate. The groups were compared us-
ing the Student’s t test, Fisher’s exact test or chi-square, as
needed. A P value less than 0.05 was considered statisti-
cally significant. The incidences of graft and patient sur-
vival were calculated for one-, two- and three-year periods
after transplantation using the Kaplan-Meier surveillance
test. The Log Rank (Mantel-Cox) test was used to compare
two groups. The data were censored at the moment the pa-
tients reached the end of study period. The graft function
was determined by the estimated glomerular filtration rate
(eGFR) calculated by the Cockroft-Gault formula.
RESULTS
Diagnostics of the polyoma BK virus was performed in 46
of 50 patients included in the study. Two patients had died
within the first three months of study (one due to acute pan-
creatitis with consecutive colon perforation and acute peri-
tonitis, the other due to pulmonary artery thrombo-
embolism), one patient had a primary non-functioning graft
and another patient underwent transplantectomy due to re-
nal artery thrombosis.
Polyoma BK virus infection was diagnosed in 16 patients.
PCR testing showed BK viruria in 16 (35%) patients and
BK viremia in 13 (28%) of 46 patients. BK viruria and BK
viremia were not always diagnosed at the same time. In
most cases, BK viruria was detected first, and viruria and
viremia during the next examination. After therapy modifi-
cation BK viremia disappeared first and viruria later. Three
patients had only BK viruria without consecutive develop-
ment of BK viremia, and 13 patients had both BK viruria
and viremia. Seven (53%) of 13 patients with BK viremia
developed BKV nephropathy. The diagnosis of BKV
nephropathy was confirmed by characteristic cytopathic
changes found on kidney graft biopsy. The other five pa-
tients recovered from BK viremia and after five years still
had a functioning graft; one patient with a functioning graft
died due to acute myocardial infarction 58 months after
transplantation. All three patients with BK viruria recovered
from it and had a functioning graft within five years after
transplantation. Five (71%) of seven patients with BKV
nephropathy lost their grafts within five years after trans-
plantation. One patient, who lost his graft due to polyoma
BKV nephropathy, has received a second transplant 59
months after primary surgery. The second transplant had
good function and there were no signs of repeated polyoma
BKV infection until the end of the study.
The 46 patients to whom screening for polyoma BK virus
was completed by the end of the first post-transplant year
were divided into four groups: group 1 (n = 30) – BKV in-
fection was not diagnosed, group 2 (n = 3) — BKV viruria
was diagnosed, group 3 (n = 6) — BKV viruria and
viremia were diagnosed and group 4 (n = 7) — BKV
viruria, viremia and BKV nephropathy were diagnosed.
BKVN did not develop in the first three months of the
study, but six months later it was diagnosed in four (9%)
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patients who previously had viruria and viremia. On the
ninth month new BKVN cases were not diagnosed. After
twelve months BKVN had developed in three (6%) more
patients.
Patient survival. Two of 50 (4%) patients died during the
first three post-transplant months (one due to acute pancre-
atitis with consecutive colon perforation and acute peritoni-
tis, the other due to pulmonary artery thromboembolism).
Two patients lost their grafts during the first three study
months (one patient had a primary non-function graft and
the other — renal arterial thrombosis, infarctions and necro-
sis with subsequent transplantectomy) and these were not
included for further monitoring and continued hemodia-
lysis. All 46 patients who were monitored for BKV infec-
tion during the study were alive at the end of the first study
year. One-year patient survival was 96% (Fig. 1).
One year later three (6%) patients had died and 43 patients
were alive. The causes of death were: melanoma with multi-
ple metastases, hepatic cirrhosis and coronary heart disease
with acute myocardial infarction. Only one of the deceased
patients (cause of the death — acute myocardial infarction)
was previously diagnosed for BK viremia and BKVN. The
two-year patient survival was 90%.
Overall five-year patient survival was 82.6%. During the
third to fifth post-transplant years 4 (8%) patients died. The
causes of death were acute myocardial infarction, hyperten-
sive crisis and for two patients the cause of death was not
known. The patient who died due to acute myocardial in-
farction had previously diagnosed BK viruria and viremia,
the others did not have active BK virus infection. Therefore,
five-year patient survival was 81.3% in the patient group
with BKV infection, and 83.3% in the patient group without
BKV infection. The death of patients was not related to ei-
ther to BK viruria or BK viremia or BK virus nephropathy.
In summary, five-year patient survival was 100% in group
2, 83.3% in group 1 similar to group 3 and 71.4% in group
4 (P = NS).
Graft survival. At the end of the first year, 46 of 50 pa-
tients had a functioning kidney graft and thus one-year graft
survival was 92% (Fig. 2). Six grafts were lost during the
Fig. 1. Patient survival after kidney trans-
plantation. BKV, BK virus.
Fig. 2. Graft survival after kidney transplan-
tation. BKV, BK virus.
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second year, two of them due to BKVN, one due to acute
rejection and chronic allograft nephropathy and three due to
patient death. In addition, one patients who was previously
diagnosed for BKVN. Thus, after two years, grafts did not
function in three of seven patients with BKVN and in three
of 39 in patients without BKVN (42% vs 7%, P <0.01).
Overall 2-year graft survival was 80%. Two-year graft sur-
vival was 75% for patients with active BKV infection and,
82% (P = NS) for patients without active BKV infection.
Overall five-year graft survival was 76.1% for patients
screened for BKV infection. Graft survival was 68.8 % in
patients with active BKV infection and 80% (P = NS) in pa-
tients without BKV infection. Five more grafts had been
lost by five years after transplantation. The cause of graft
loss was death of a patient with a functioning graft in four
cases, one of whom had been previously diagnosed for
BKVN. One graft was lost due to repeated urinary tract in-
fections and chronic allograft nephropathy. Five-year graft
survival was 82.1% for patients without developed BKVN
and 42.9% for patients with diagnosed BKVN (P < 0.01).
Five-year graft survival was 80% in group 1, 100% in group
2, 83.3% in group 3 and 42.9% in group 4 (P < 0.01).
Rejection. Acute rejection occurred in 22 (48%) of 46 pa-
tients by five years after transplantation. Fifteen (33%) pa-
tients experienced acute rejection in the first year after
transplantation and seven (15%) patients suffered acute re-
jection during the subsequent 2–5 years. Banff-grade I re-
jections occurred in 16 (35%) patients, grade II rejections in
4 (9%) patients and two (4.5%) patients had grade III acute
rejection. In nine cases rejection was steroid resistant and
was treated with ATG. In four of 15 patients who experi-
enced acute rejection, active BKV infection (P < 0.05) ap-
peared later. One of those 15 patients developed BKVN at
the end of first post-transplant year (P = NS). However, the
grade of acute rejection was not related to reactivation rate
of BKV infection. The development of active BKV infec-
tion or BKVN was not associated with treatment of rejec-
tion with ATG year (P = NS).
Graft function. Mean serum creatinine was 140 ± 8
mkmol/l and GFR level was 63.52 ± 3,19 ml/min one year
after transplantation. At the end of second year mean serum
creatinine was 130 ± 5 mkmol/l and GFR was 67.6 ± 2.9
ml/min for patients with a functioning graft.
The overall mean five-year serum creatinine level was 140
± 40 mkmol/l and the mean five-year GFR was 57.6 ± 17.0
ml/min in patients with a functioning graft. Five years after
transplantation, patients without BKV infection had a sig-
nificantly lower serum creatinine level (130 ± 30 mkmol/l
vs 160 ± 50 mkmol/l, P < 0.05) and better GFR (60.9 ± 17.0
ml/min vs 52.1 ± 16.6 ml/min, P = NS) compared with pa-
tients who had previous active BKV infection.
Influence of reduction of immunosuppression in patients
with BKV infection. No BKV-specific reagents have yet
been developed. Currently, the more commonly used and
accepted strategy for first-line treatment of active BKV in-
fection and BKVN is reduction of immunosuppression, but
schedules vary from study to study.
At the time of transplant all patients were prescribed
prednisolone. After one year, prednisolone was discontin-
ued in three patients with active BKV infection and in eight
patients without active BKV infection. Five years after
transplantation 21 patients still received prednisolone; of
those 14 were in group 1, two in group 2, three in group 3
and two in group 4.
At the time of transplantation, all patients were prescribed
MMF. After one year, for two patients (one due to CMV in-
fection, another due to BKV nephropathy) treatment was
switched to AZA and for two antimetabolite was discontin-
ued (both due to gastrointestinal side effects and one of
them with BK viremia and viruria). Thirty four of 35 pa-
tients with a functioning graft still received MMF at five
years after transplantation and only one patient with previ-
ous BKVN had AZA.
At the time of transplantation all patients were prescribed
CSA. Within the first post-transplant month treatment for
two patients was switched to TAC due to severe rejection
and later BKVN developed in one of them. During the next
month one more patient had treatment switched to TAC and
BKVN developed in this case. At the end of the first year,
CSA was given to 13 patients with active BKV infection
and 27 without active BKV infection (P = NS). BKVN de-
veloped in two patients with TAC and five patients with
CSA in maintenance immunosuppression. Twenty five of
35 patients with a functioning graft still received CSA by
the five years after transplantation and two of them had suf-
fered BKVN. Five of 35 patients received TAC and one of
them had previous BKVN.
Sirolimus was prescribed to four patients, all without previ-
ous BKV infection at five years after transplant.
After reduction of immunosuppression, BK viremia contin-
ued in six of 13 patients and viruria in all three patients. At
the end of the first post-transplant year BK viremia still per-
sisted in five of seven patients with BKVN and in four cases
grafts were lost — two due to BKVN and two due to patient
death.
DISCUSSION
This study demonstrated a good long-term graft function,
but only for grafts what were not lost up to that time. Only
70% of recipients initially included in the study had func-
tioning grafts five years after transplantation. A similar
five-year graft survival rate (72% for non-expanded criteria
donors and 57% for expanded criteria donors) was reported
as outcome of transplants performed in the United States
between 1999 and 2009 (Axelrod et al., 2010).
There are several findings from our study. Firstly, the rate
of active BKV was 35% and incidence of BKVN was 15%
one year after kidney transplantation surgery in our centre
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in the year 2007. These results are compatible with reports
from other centres (Dharnidharka et al., 2009; Koukoulaki
et al., 2009), but the incidence is quite high, probably due to
more vigilant detection of BKV infection and usage of in-
duction immunosuppression in all cases. Active BKV infec-
tion in the first year after transplantation was related to
worse graft function subsequently. Secondly, the study
identified that patients with any grade of acute rejection are
at risk for later reactivation of BKV infection. This was
confirmed by analysis of the role of specific immunosup-
pressive agents and lack of a significant relationship with
development of active BKV infection. The degree of
immunosuppression was sufficiently high and minimisation
of immunosuppression upon detection of BK viremia was
safe. In the majority of patients no acute rejection devel-
oped afterwards, except in one patient. Thirdly, we ob-
served that, when reduction in immunosuppression was
made as required, viruria continued in all patients, and
viremia resumed in half of patients in a subsequent 3 to 6
month period. Finally, the results demonstrate significant
graft loss in the patient group with persistent viremia and
developed BKVN. Thus, we can conclude that BKVN is
nonreversible and immunosuppression reduction should be
started when active BKV infection is diagnosed. The study
has several limitations, including absence of quantitative vi-
rus DNA detection and lack of prolonged BKV detection
beyond the first post-transplant year.
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POLIOMAS BK VÎRUSA SKRÎNINGA ATTÂLIE REZULTÂTI PACIENTIEM AR NIERES TRANSPLANTÂTU
Poliomas BK vîrusa infekcija tika prospektîvi diagnosticçta 50 pacientiem, kam nieres transplantâcija bija veikta 2007. gadâ. Vîrusa
genomu secîbu klâtbûtnes konstatçðanai asins plazmas DNS (virçmija) un urîna DNS (virûrija) tika izmantota polimerâzes íçdes reakcijas
metode ar iekðçjo praimçðanu. Vîrusa genoma secîbu skrîninga rezultâti bija pieejami 92% (n = 46) no pçtîjumâ iesaistîtajiem pacientiem.
Òemot to vçrâ, pacienti tika iedalîti èetrâs grupâs: ar poliomas BK vîrusu neinficçti pacienti (1. grupa, n = 30), pacienti ar virûriju (2. grupa,
n = 3), pacienti ar virçmiju (3. grupa, n = 6) un pacienti, kuriem attîstîjâs BK vîrusa nefropâtija (4. grupa, n = 7). Aktîva poliomas BK vîrusa
infekcija trim pacientiem tika diagnosticçta jau pirmâ pçctransplantâcijas mçneða laikâ, bet visvairâk pacientu (n = 8) ar aktîvu poliomas
BK vîrusa infekciju bija seðus mçneðus pçc operâcijas. Nieres transplantâtu piecu gadu dzîvildze pacientiem ar virûriju un/vai virçmiju bija
69%, bet pacientiem bez infekcijas — 80% (P = NS). Vislabâkâ transplantâtu funkcija piecus gadus pçc operâcijas bija pacientiem 1. grupâ
(vidçjais seruma kreatinîns 130 mkmol/l un glomerulârâs filtrâcijas âtrums (GFÂ) 60,9 ml/min) un vissliktâkâ — 4. grupâ (vidçjais seruma
kreatinîns 180 mkmol/l un GFÂ 52,31 ml/min). Pacientu piecu gadu dzîvildze bija 82,6%, un tâ nebija atðíirîga pacientiem ar vai bez
poliomas BK vîrusa infekcijas.
Received 16 November 2012
51Proc. Latvian Acad. Sci., Section B, Vol. 67 (2013), No. 1.
